Quality of life assessment in clinical practice in haemophilia treatment

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 22-29

  Gringeri, Alessandro ^a   Mantovani, L ^b   Mackensen, S V ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Assessment; Health economics; Outcome research; Patient rated outcomes; Quality of life

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ASSESSMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEMOPHILIA; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE MANAGEMENT; SELF REPORT; WELLBEING;

ADULT; HEALTH STATUS INDICATORS; HEMOPHILIA A; HUMANS; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33646164906     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01257.x     Document Type: Article

References (46)

1. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life in hemophilia complicated by inhibitors: The COCIS Study Group. Blood 2003; 102: 2358-63.
3. Cella DF, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology 1990; 4: 29-38.
4. Bowling A. Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales, 2nd edn. Buckingham: Open University Press, 2001.
5. von Mackensen S, Gringeri A. Quality of life in haemophilia. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Haemophilia. Oxford: Blackwell Publisher, 2004: 345-50.
6. Trimestra AHM, Smit C, Van der Ploeg HM, Briet E, Rosendal FR. Two decades of haemophilia treatment in the Netherlands, 1972-1992. Haemophilia 1995; 1: 165-71.
7. Barr RD, Saleh M, Furlong W et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002; 71: 152-60.
8. Goudemand J. Treatment of patients with inhibitors: Cost issues. Haemophilia 1999; 5: 397-401.
9. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
10. Lippert B, Berger K, Berntorp E et al. Cost effectiveness of haemophilia treatment: A cross-national assessment. Blood Coagul Fibrinolysis 2005; 16: 477-85.
11. Kind P. The EuroQol instrument: An index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven, 1996: 191-201.
12. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996; 34: 702-22.
13. Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002; 20: 759-74.
14. Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia 2004; 10 (Suppl. 1): 50-7.
15. Revicki DA. Patient assessment of treatment satisfaction: Methods and practical issues. GUT 2004; 53 (Suppl. IV): Iv40-4.
16. Eiser C, Morse R. A review of measure of quality of life for children with chronic illness. Arch Dis Child 2001; 84: 205-11.
17. Ware JE, Snow KK, Kosiniski M, Gandek B. SF-36 Health Survey Manual and Interpretation. Guide Boston, MA: New England Medical Centre, 1993.
18. Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: Tests of the universality of quality of life in 15 different cultural groups worldwide. Health Psychol 1999; 18: 495-505.
19. Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: First psychometric and content analytical results. Qual Life Res 1998; 7: 399-407.
20. Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care 1999; 37: 126-39.
21. Bullinger M, von Mackensen S, Fischer K et-al. Pilot testing of the Haemo-QoL quality of life questionnaire for haemophiliac children in six European countries. Haemophilia 2002; 8 (Suppl. 2): 47-54.
22. Young N, Bradley C, Blanchette V, Wakefield C, Barnard D, McCusker P. Development of a health-related quality of life measure for boys with haemophilia: The Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT). Haemophilia 2004, 10 (Suppl. 1): 34-43.
23. Von Mackensen S, Bullinger M, the Haemo-QoL Group. Development and testing of an instrument to assess the quality of life of children with haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10 (Suppl. 1): 17-25.
24. Flood E, Szende A, Rentz A et al. Health-related quality of life in adults with hemophilia: The patient perspective. J Thromb Haemost 2003; 1 (Suppl. 1): Abstract number P0657.
25. Remor E, Young NL, von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia 2004; 10 (Suppl. 4): 30-4.
26. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia ? Pediatr Blood Cancer (in press).
27. von Mackensen S, Gringeri A, Santoni L et al. Development and pilot testing of a disease-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL). Blood 2004; 104: 2214 (abstract).
28. Trudeau E, Dias C, Lambert T et al. Development of the haemophilia age-group specific quality of life questionnaire. Value Health 2003; 6: 744 [abstract PHL11].
29. Pollak E, Mühlan H, von Mackensen S, Bullinger M, the Haemo-QoL Group. The Haemo-QoL Index. Developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia (submitted to).
30. Gringeri A. Prospective controlled studies on prophylaxis: An Italian approach. Haemophilia 2003; 9 (Suppl. 1): 38-42.
31. v. Mackensen S, Gringeri A, Ravera S, the HAEM-A-QoL Group. Validation of the haemophilia-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL). Haematologica 2005; 90 (Suppl. 2): 116-7 [abstract 0290].
32. von Mackensen S, Scalone L, Ravera S, Mantovani L, Gringeri A, for the COCHE Study Group. Assessment of health-related quality of life in patients with haemophilia with the newly developed haemophilia-specific instrument (Haem-A-QoL). Value Health 2005; 8: A127 [abstract PHM5].
33. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia, PA: Lippincott-Raven Publishers, 1996: 253-65.
34. Luce D, Tukey J. Simultaneous conjoint measurement: A new type of fundamental measurement. J Math Psychol 1964; 1: 1-2.
35. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR III. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002; 162: 1361-6.
36. Ryan M, Hughes J. Using conjoint analysis to value surgical versus medical management of miscarriage. Health Econ 1997; 6: 261-73.
37. Monahan PE, Aledort LM. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Am J Hematol 2004; 77: 346-50.
38. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment. Haemophilia 2005; 11: 589-97.
39. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the management of satisfaction with treatment. Am J Manag Care 1997; 3: 579-94.
40. von Mackensen S, Gringeri A, Mantovani L, Skovlund SE, Mannucci PM. Development of the first disease-specific treatment satisfaction questionnaire for patients with haemophilia (Hemo-Sat A). Blood 2002; 100; (abstract).
41. von Mackensen S, Gringeri A, Mantovani L et al. Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo-Sat A). Haemophilia 2004; 10 (Suppl. 3): 126 (abstract).
42. Mackensen Sv, Gringeri A, Scalone L, Mantovani L, the COCHE Study Group. How satisfied are patients in Italy with the treatment of their haemophilia? Results of the COCHE study. Haematologica 2005; 90 (Suppl. 2): 310 [abstract 0778].
43. Van Genderen FR, Van Meeteren NLU, Van der Bom JG et al. Functional consequences of haemophilia in adults: The development of the haemophilia activities list. Haemophilia 2004; 10: 565-71.
44. von Mackensen S, Czepa D, Hilberg T, Ziezio R, Herbsleb M. Subjective assessment of the effects of a sports therapy programme (HEP) for adult haemophilia patients (HEP-test). Haemophilia (abstract submitted).
45. Poonnoose PM, Manigandan C, Thomas R et al. Functional independence score in haemophilia: A new performance-based instrument to measure disability. Haemophilia 2005; 11: 598-602.
46. Hilberg T, Herbsleb M, Puta C, Gabriel HW, Schramm W. Physical training increases isometric muscular strength and proprioceptive performance in haemophilic subjects. Haemophilia 2003; 9: 86-93.